# Ameliorating Contrast Induced Nephropathy After Coronary Angiography

Study · id `cardio:ct-nct06139952` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06139952](<https://clinicaltrials.gov/study/NCT06139952>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06139952

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT06139952. Randomized; single masking; primary purpose prevention. Start 2023-12-01 (actual); primary completion 2024-03-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT06139952, source copy `cardio:ctgov-nct06139952-2024-07-11`, retrieved 2026-10-26)
- Started: 2023-12-01 (actual) (ClinicalTrials.gov record NCT06139952, source copy `cardio:ctgov-nct06139952-2024-07-11`, retrieved 2026-10-26)
- Primary completion: 2024-03-01 (actual) (ClinicalTrials.gov record NCT06139952, source copy `cardio:ctgov-nct06139952-2024-07-11`, retrieved 2026-10-26)
- Completion: 2024-07-01 (actual) (ClinicalTrials.gov record NCT06139952, source copy `cardio:ctgov-nct06139952-2024-07-11`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT06139952, source copy `cardio:ctgov-nct06139952-2024-07-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06139952-2024-07-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ameliorating Contrast Induced Nephropathy After Coronary Angiography
- Condition: Coronary Artery Disease
- Condition: Nephropathy; Toxic, Drugs
- Intervention (Drug): Atorvastatin 80mg
- Intervention (Drug): N-acetyl cysteine
- Intervention (Other): Normal Saline
- Lead sponsor: Ain Shams University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Ain Shams University (`cardio:org-ain-shams-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Preventing Contrast-Induced Acute Kidney Injury in Egyptian Patients Undergoing Coronary Angiography: A Randomized Controlled Trial (`cardio:pubmed-41701447`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a7f7ffc4abc042623388e192b03f9c10ed3f9b0caedbf1b1254e4bbe7543f0b0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
